2 ABSTRACT ERK1 and ERK2 (ERK1/2) are central to the regulation of cell division, growth and survival.
They are activated by phosphorylation of the Thr-and the Tyr-residues in their Thr-Glu-Tyr activation loops. The dogma is that dually-phosphorylated ERK1/2 constitute the principal activities in intact cells. We previously showed that, in neonatal rat cardiac myocytes, endothelin-1 and phorbol 12-myristate 13-acetate (PMA) powerfully and rapidly (maximal at ~5 min) activate ERK1/2. Here, we show that dually-phosphorylated ERK1/2 rapidly (< 2 min) appear in the nucleus following stimulation with endothelin-1. We characterized the active ERK1/2 species in myocytes exposed to endothelin-1 or PMA using MonoQ FPLC.
Unexpectedly, two peaks of ERK1 and two peaks of ERK2 activity were resolved using in vitro kinase assays. One of each of these represented the dually-phosphorylated species. The other two represented activities for ERK1 or ERK2 which were phosphorylated solely on the Thr-residue. Monophosphothreonyl ERK1/2 represented maximally ~30% of total ERK1/2 activity after stimulation with endothelin-1 or PMA, and their k cat values were estimated to be minimally ~30% of the dually-phosphorylated species. Appearance of monophosphothreonyl ERK1/2 was rapid but delayed in comparison with dually-phosphorylated ERK1/2. Of 10 agonists studied, endothelin-1 and PMA were most effective in terms of ERK1/2 activation and in stimulating the appearance of monophosphothreonyl and dually-phosphorylated ERK1/2. Thus, enzymically-active monophosphothreonyl ERK1/2 are formed endogenously following activation of the ERK1/2 cascade and we suggest that monophosphothreonyl ERK1/2 arise by protein tyrosine phosphatase-mediated dephosphorylation of duallyphosphorylated ERK1/2. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 4
Introduction
The related prototypic MAPKs, ERK1 and ERK2 (ERK1/2), are Pro-directed Ser-/Thr-protein kinases which regulate cell growth, division and survival through their effects on gene expression and other cellular processes [1] [2] [3] . In many dividing cells (including cell lines), growth factor-binding to receptor protein Tyr-kinases leads to activation of ERK1/2 [4, 5] . This is also the case in primary cultures of (terminally-differentiated) neonatal rat cardiac myocytes [6, 7] but here robust ERK1/2 activation is also induced by Gq proteincoupled receptor-/PKC-dependent pathways [8] . Thus, ligands such as endothelin-1 (ET-1)
and tumour-promoting phorbol esters (such as phorbol 12-myristate 13-acetate, PMA) essentially stoicheiometrically activate ERK1/2 in these cells [7] .
ERK1/2 are the final components of a protein kinase signaling cascade in which members of the Raf MAPK kinase kinase family (Raf-1, A-Raf and B-Raf) phosphorylate and activate MAPK kinases 1 and 2 (MKK1/2), which in turn phosphorylate and activate ERK1/2 [1] . In all 'classical' MAPKs (ERK1/2, JNKs and p38-MAPKα/β) and some 'novel'
MAPKs, activation involves the phosphorylation of a Tyr-residue and a Thr-residue in the activation loop Thr-Xaa-Tyr sequence (Thr-Glu-Tyr in ERK1/2) to produce the duallyphosphorylated MAPK species [1] . In mouse or rat, the relevant residues are Thr-203 and Tyr-205 in ERK1, and Thr-183 and Tyr-185 in ERK2. The general belief is that phosphorylation of both Tyr-and Thr-is necessary for activation of ERK1/2. Activated ERK1 and ERK2 from cardiac myocytes exposed to ET-1 or PMA have been separated into two discrete peaks of activity by MonoQ Fast Protein Liquid Chromatography (FPLC) with ERK2 eluting at a lower NaCl concentration [6, 9] . We show here that each of these peaks of ERK1 or ERK2 activity can be resolved further into two 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   5 separate peaks. One of these two resolved peaks of ERK1 or ERK2 is dually-phosphorylated [(pT-E-pY)ERK1/2], whereas the second peak is ERK1 or ERK2 monophosphosphorylated on the Thr-residue [(pT-E-Y)ERK1/2]. The important conclusion is that monophosphothreonyl-ERK1/2 can be formed endogenously in cells and contributes significantly to overall ERK1/2 activity.
Materials and methods

Antibodies
The antibody against total ERK1/2 was a rabbit polyclonal from Cell Signaling 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   6 
Cardiac myocyte isolation and culture
Primary cultures of ventricular cardiac myocytes were prepared from 1-to 2-day-old Sprague-Dawley rats by an adaptation of the method of Iwaki et al. [11] as described elsewhere [12] . Hearts were removed, ventricles were dissected away from atria, and ventricular myocytes were dissociated by serial digestion with 0.4 mg/ml collagenase and 0.6 mg/ml pancreatin in sterile digestion buffer (116 mM NaCl, 20 mM HEPES, 0.8 mM The cells were pre-plated on plastic Primaria tissue culture dishes (30 min). The noncardiomyocytes adhere to the dishes whereas the cardiac myocytes remain unattached. For biochemistry experiments, the non-adherent viable cardiac myocytes from the pre-plates were plated at a density of 4 × 10 6 cells/dish on 60 mm Primaria dishes pre-coated at room temperature with sterile 1% (w/v) gelatin (Sigma-Aldrich UK). For immunostaining experiments, cardiac myocytes were plated at 2 × 10 6 cells/dish on 35 mm Primaria dishes containing glass coverslips pre-coated with gelatin as above followed by laminin (SigmaAldrich UK, 20 µg/ml in PBS). After 18 h, myocytes were confluent and beating spontaneously. Unless they were to be infected with adenovirus (AdV), serum was then withdrawn and myocytes were incubated in maintenance medium [Dulbecco's modified 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 Eagle's medium/medium 199 (4:1 (v/v), 100 units/ml of both penicillin and streptomycin] for a further 24 h.
Immunofluorescence microscopy
Cardiac myocytes were exposed to ET-1 (100 nM), then washed 3 × with PBS and Fluorescence microscopy was performed using a Zeiss Axio Observer Z1 inverted microscope equipped with a Zeiss LSM710 confocal imaging system, and using a PlanApochromat 63×/1.4 oil-immersion objective. Standard excitation and emission presets were chosen for Hoechst 33258, Alexa 488, and Texas Red dyes, which were imaged sequentially to eliminate fluorescence bleed-through. All fields were captured at a resolution of 512 × 
AdV vector for FLAG-ERK2
The AdV-FLAG-ERK2 vector was prepared using the AdEasy™ XL Adenoviral
Vector System (Stratagene) using the general methodology described previously [13] . The FLAG sequence (placed 3' to an initiation codon) was introduced into the pShuttle-CMV vector and the mouse ERK2 coding sequence was placed in frame and 3' to the FLAG tag.
The FLAG sequence was first introduced between the BglII and KpnI restriction sites in the 
MonoQ FPLC
After the various treatments, cardiac myocytes were washed 3× with ice-cold PBS, Radioactivity was measured by Čerenkov radiation counting.
In some cases, ERK1/2 activities were examined by 'in-gel' MBP kinase assays.
Fractions from FPLC were denatured with SDS-PAGE sample buffer and subjected to SDS-PAGE in 10% polyacrylamide gels containing 0.5 mg/ml MBP incorporated covalently into the gel matrix. After electrophoresis, SDS was removed from the gel by washing ( 
Data interpretation
Graphs were constructed using GraphPad Prism 4.0 software and results are presented as means ± S.E.M. Areas under the curves were calculated using Origin Pro 8 software.
RESULTS
Immunofluorescence microscopy
Immunofluorescence microscopy showed that (pT-E-pY)ERK1/2 appeared transiently in cardiac myocytes exposed to 100 nM ET-1 ( Fig. 1) . At zero time, some background staining of (pT-E-pY)ERK1/2 was detectable ( Fig. 1) . By 2 min, staining had increased dramatically in the nucleus and, to a lesser extent, in the cytoplasm. After 5 min, staining was maximal in both compartments but, by 10 min, staining was declining in both.
This transience is consistent with enzyme activity measurements [6] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   13 
MonoQ FPLC of extracts of cardiac myocytes exposed to ET-1 or PMA
By reducing the flow rate and using a shallow NaCl gradient, we separated five peaks of MBP kinase activity (peak A and peaks I-IV) in extracts of cardiac myocytes exposed for 5 min to 100 nM ET-1 ( Fig. 2A ) or 1 µM PMA (Fig. 2B) , conditions that maximally activate ERK1/2 in these cells [7, 9] . Activities in Peaks I-IV with ET-1 or PMA were about 6-fold greater than in the controls. PD184352 is an allosteric inhibitor of MKK1/2 [14] . Exposure of cardiac myocytes to PD184352 (2 µM, 15 min) reduced MBP kinase activities to below control values and prevented subsequent activation of MBP kinase peaks I-IV by ET-1 (Fig.   2C ). These results, together with previous findings [6, 9] , suggest that the MBP kinase activities in Peaks I-IV represent either ERK1 and ERK2 themselves, or that one or more of the activities represents downstream effector protein kinases activated by ERK1/2.
The MonoQ fractions in Fig. 2A -B, were immunoblotted for total (i.e. phosphorylated + non-phosphorylated) ERK1/2 (Fig. 2D) . In extracts from control cells, 42 kDa ERK2 eluted over fractions [16] [17] [18] [19] [20] [21] [22] (maximal in fractions [18] [19] and 44 kDa ERK1 eluted over fractions 24-29 (maximal in fractions 26-27) (Fig. 2D) . In extracts of cells exposed to ET-1 or PMA, ERK1 and ERK2 eluted at slightly higher NaCl concentrations because of the negative charges introduced by phosphorylation. MBP kinases ( Fig. 2A-B ) in Peak I (peak fractions 19-20 eluting at ~0.14 M NaCl) and Peak II (peak fractions 23-24 eluting at ~0.16 M NaCl) contained ERK2 (Fig. 2D ). Peak III (peak fractions 29-30 eluting at ~0.17 M NaCl, and overlapping with Peak II) contained ERK1 as did Peak IV (peak fractions 40-41 eluting at ~0.20 M NaCl) ( Fig. 2A,B,D) .
Selected fractions were immunoblotted with antibodies recognising various phosphorylated forms of ERK1/2. In extracts of myocytes exposed to ET-1 or PMA ,   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   14 antibodies recognising (pT-E-pY)ERK1/2 showed that Peak II (fractions 23 and 25)
contained (pT-E-pY)ERK2 and Peak IV (fraction 41) contained (pT-E-pY)ERK1 (Fig. 2E ).
Monoclonal antibodies selective for (pT-E-Y)ERK1/2 [10] showed that Peak I (fractions 18 and 20) contained (pT-E-Y)ERK2 and Peak III (fractions 28 and 30) contained (pT-E-Y)ERK1 (Fig. 2E) . The (T-E-pY)ERK1/2-selective antibody [10] did not detect any significant immunoreactivity in Peaks I-IV, though it may have detected some immunoreactivity in Peak A (fraction 7) (Fig. 2E) . We cannot definitely exclude the possibility that there is some formation of (T-E-pY)ERK1/2 because the antibody may simply be unable to detect it, but we were unable to detect any signal using a variety of dilutions.
Our interpretation of these experiments is that, in addition to (pT-E-pY)ERK1/2, (pT-E-Y)ERK1/2 can be readily detected in cardiac myocytes exposed to ET-1 or PMA in intact cells and these species are enzymically active.
In addition to ERK1/2, a 46 kDa 'ERK' protein was detected in fractions 6-7 and which corresponded to the MBP kinase activity in Peak A eluting at ~0.11 M NaCl ( Fig. 2A-B ). This may be ERK1b, identified previously in Rat1 cells, which is expressed in highest abundance in heart [15] . ERK1b is an alternatively-spliced 406 residue protein containing a 26-residue insert between residues 340 and 341 in rat ERK1 [15] . In comparison with peaks I-IV, Peak A MBP kinase was relatively poorly activated (~2-fold) by ET-1 ( Fig. 2A) or PMA (Fig. 2B) .
We also performed 'in-gel' MBP kinase assays [7] on selected fractions. Such assays require the renaturation of denatured phosphorylated ERK1/2. Interestingly, only the duallyphosphorylated forms (fractions 21, 22, 38 and 39) of ERK1 (migrating at 44 kDa) and ERK2
(migrating at 42 kDa) were able to renature (Fig. 2F ) and phosphorylate MBP. 
Relative contributions and specific activities of phospho-ERK1/2 species
Integration of the curves in Fig. 2A-B , showed that the enzymic activity attributable to (pT-E-Y)ERK1/2 is considerable and represents ~30% of the total MBP kinase activity in cardiac myocytes exposed to 100 nM ET-1 (9 separate preparations of cardiac myocytes) or 1 µM PMA for 5 min (5 separate preparations of myocytes).
Approximate relative specific activities (turnover numbers or k cat ) of (pT-E-Y)ERK1/2 and (pT-E-pY)ERK1/2 were estimated from data in Fig. 2A,B ,E on the following basis. In extracts of control cardiac myocytes, antibodies against total ERK1/2 or any of the phospho-ERK1/2 species did not detect significant immunoreactivity in fractions 23 and 41.
On activation of ERK1/2 by ET-1 or PMA, immunoreactivity became detectable with antibodies against total ERK1/2 or (pT-E-pY)ERK1/2, but not (pT-E-Y)ERK1/2, in fractions 23 (ERK2) and 41 (ERK1). Thus, essentially all enzymic activity and total immunoreactivity in these fractions was attributable to (pT-E-pY)ERK1/2. The ratio of measured enzymic activity to total ERK1/2 in fractions 23 and 41 thus provided a measure of the specific activity for (pT-E-pY)ERK1/2
For fractions 20 and 30, antibodies against total ERK1/2 detected immunoreactivity but negligible enzymic activity in control incubations of cardiac myocytes. However, both immunoreactivity and significant enzymic activity was detected in cardiac myocytes exposed to ET-1 or PMA but (pT-E-Y)ERK1/2 were the only phosphorylated species detectable. The ratio of measured enzymic activity to total ERK1/2 in fractions 20 and 30 thus provided a minimum measure of the specific activity for (pT-E-Y)ERK1/2 because the contribution of inactive ERK1/2 to the denominator cannot be assessed. From the data shown, the minimum specific activities (mean ± S.E., n = 5) of (pT-E-Y)ERK1 and (pT-E-Y)ERK2 were   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   16 calculated to be 29 ± 1% and 30 ± 2% of those of (pT-E-pY)ERK1 and (pT-E-pY)ERK2, respectively.
Infection of cardiac myocytes with AdV.FLAG-ERK2.
In order to ensure that activities in Peaks I and III ( Fig. 2A-B) were not MBP kinases activated downstream from ERK1/2, we infected cardiac myocytes with AdV.FLAG-ERK2.
Infected and uninfected myocytes were exposed to 100 nM ET-1 (5 min) and MBP kinase activities measured following MonoQ FPLC. The additional negative charge of the FLAG epitope shifted the elution of FLAG-ERK2 activity to a position between Peaks III and IV (Fig. 3A) . Treatment of AdV.FLAG-ERK2-infected myocytes with ET-1 resulted in a large increase in MBP kinase activity in fractions 46 -62 (note that fraction numbers in Fig. 3 are not comparable to those in Fig. 2 because fraction size was reduced). Fractions 48 (minor peak of FLAG-ERK2 activity) and 54 (major peak of FLAG-ERK2 activity) were characterised further (Fig. 3B ). As expected, total ERK2 or FLAG immunoreactivity was present in much greater abundance in fractions 48 and 54 from AdV.FLAG-ERK2-infected myocytes (control or ET-1-treated) than in uninfected myocytes (Fig. 3B) . (pT-EpY)ERK1/2 were not detected in uninfected or AdV.FLAG-ERK2-infected control myocytes, though there was some (pT-E-Y)ERK1/2 immunoreactivity detectable in fraction 48 of the AdV.FLAG-ERK2-infected controls (Fig. 3B) . We do not understand the reasons for this. In
AdV.FLAG-ERK2-infected myocytes exposed to ET-1, a strong (pT-E-pY)ERK2 signal was detected in fraction 54 with a weaker signal in fraction 48 (Fig. 3B) . Conversely, (pT-E-Y)ERK2 was readily detected in fraction 48 with a weaker signal in fraction 54 (Fig. 3B ).
These data confirm that all the MBP kinase activities in peaks I-IV ( Fig. 2A-B 
Time courses of ERK1/2 phosphorylation
Cardiac myocytes were exposed to 100 nM ET-1 for various times and cell extracts were immunoblotted directly with (pT-E-pY)ERK1/2 (Fig. 4A) or (pT-E-Y)ERK1/2 antibodies (Fig. 4B) . (pT-E-pY)ERK1/2 were detectable within 30 s and maximal at 1 -2 min (Fig. 4A ), whereas (pT-E-Y)ERK1/2 were not detected before 1 min but was maximal at ~ 5 min (Fig. 4B ). These findings suggest (but do not prove) a precursor-product relationship with (pT-E-Y)ERK1/2 resulting from dephosphorylation of (pT-E-pY)ERK1/2. The time course of activation of ERK1/2 by ET-1 was also examined by MonoQ FPLC (Fig. 5A) .
Areas under individual peaks were integrated and plotted against time (Fig. 5B) . Peak II
[(pT-E-pY)ERK2] and Peak IV [(pT-E-pY)ERK2
] were detectable within 30 s, rose to a maximum at 1 -2 min, then gradually declined over the subsequent 40 min (Fig. 5A-B ). 
Peak I [(pT-E-Y)ERK2] and Peak III [(pT-E-Y)ERK1
Comparison of agonist efficacy in (pT-E-Y)ERK1/2 and (pT-E-pY)ERK1/2 formation in cardiac myocytes
Numerous agonists stimulate ERK1/2 activities and phosphorylation in cardiac myocytes. We compared the MonoQ FPLC activity profiles for 10 agonists (Fig. 6A ) and derived the relative contribution of each peak of activity to the total activity (i.e. the sum of activities in all four peaks) using activation by ET-1 (100 nM, 5 min) as an internal standard and taking it as 100%. The time of sampling was when the response to each agonist was maximal and maximally-effective concentrations were chosen. In terms of total activity, ET-1 and PMA caused the greatest activation and H 2 O 2 the least ( relative to total activity (Fig. 6B,F ). This contrasted with the other monophosphorylated species in Peak III [(pT-E-Y)ERK1, Fig. 6D ] where the abundance of (pT-E-Y)ERK1 was proportional to the total ERK1/2 activities (Fig. 6G) . Thus the relative abundance of (pT-E-Y)ERK reflects the abundance of total (pT-E-pY)ERK only in the case of ERK1.
Discussion
Classically, activation of ERK1/2 involves phosphorylation of the Thr-and Tyrresidues in the activation loop Thr-Glu-Tyr by the dual-specificity kinases, MKK1/2 in an   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   19 ordered, 'distributive' manner [1, [22] [23] [24] [25] [26] . In non-phosphorylated ERK2 (and presumably ERK1), the activation loop Tyr-lies in a hydrophobic pocket with its -OH group buried, whilst the Thr-is on the surface. First of all, Tyr-185 is phosphorylated by MKK1/2 causing a conformational change, with the phospho-Tyr-side chain moving to the surface of the protein making four interactions with two Arg-residues and thus presumably stabilising the (T-E-pY)ERK2 conformation of the enzyme. The MKK1/2 then dissociates and second MKK1/2 binds to (T-E-pY)ERK2 and phosphorylates the Thr-residue, thereby forming a further 8 ionic contacts. The Tyr-phosphorylation is important in protein substrate recognition whereas the Thr-phosphorylation improves the geometry of the active site. This model is supported by demonstration of distinct structures for the non-phosphorylated, Tyrphosphorylated, and dually-phosphorylated forms of ERK1 [27] . The ordered mechanism has led to the conclusion that phosphorylation of both Thr-and Tyr-residues is essential for full activity of ERK1/2. It became generally assumed that monophosphorylated forms are, at best, low k cat species and, if they occur endogenously in cells in vivo, it is only in low abundances. However, an alternative interpretation is that phosphorylation of the Tyr-is an obligatory step for stabilisation of the 'transition state', and that it precedes and is required for the Thr-phosphorylation. However, once the activation loop Thr-is phosphorylated, the phosphate of phospho-Tyr could be dispensable. This may explain why, although (pT-EpY)ERK1/2 activities renatured in 'in-gel' kinase assays (Fig. 2F) , (pT-E-Y)ERK1/2 activities did not because the Tyr-phosphorylation is necessary for renaturation.
Many agonists activate ERK1/2 the ERK1/2 cascade in cardiac myocytes to varying degrees ( Fig. 6 ) with ET-1 and PMA being most potent (as we have shown previously [7, 9] ).
(pT-E-pY)ERK1/2 appeared rapidly (within 2 min) in both the nuclei and cytoplasm of cardiac myocytes exposed to ET-1 before declining (Fig. 1) , a similar response to that seen 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   20 with PMA [28] . Thus, (pT-E-pY)ERK1/2 are correctly localised to regulate ET-1-mediated transcriptional events, the majority of which are dependent on activation of the ERK1/2 cascade in cardiac myocytes [29, 30] . However, we were unconvinced that we could detect any production of (pT-E-Y)ERK1/2 by immunostaining (results not shown) and suggest that this is simply a problem with immunostaining with the (pT-E-Y)ERK1/2 antibody.
Here, we show that (pT-E-Y)ERK1/2 can be responsible for up to ~30% of total ERK1/2 activity in mammalian cells (Fig. 2) . To our knowledge, this is the first direct demonstration of significant endogenous (pT-E-Y)ERK1/2 activity in vivo. The general assumption has been that (pT-E-Y)ERK1/2 or (T-E-pY)ERK1/2 are essentially enzymicallyinactive and that, if they do occur in vivo, they only occur in low abundances. However, in vitro, recombinant (pT-E-F)ERK2 was about 7-to 8-fold more active than (T-E-F)ERK2, though the resulting activity was still <0.5% of that of (pT-E-pY)ERK2 [26, 31] . Similarly, (A-E-pY)ERK2 was about 100-fold more active than (A-E-Y)ERK2 but this was only about 2% of the activity of (pT-E-pY)ERK2. However, activation loop mutants of ERK2 was used in these experiments and these may not be of strict relevance to (T-E-Y)ERK2. Zhou and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   21 Both (pT-E-Y)ERK1/2 and (T-E-pY)ERK1/2)] have been detected by immunofluorescence or immunoblotting in intact ErbB1-overexpressing CHO cells following short-term (up to 15 min) exposure to EGF [10] . They were thought to arise from selective dephosphorylation of (pT-E-pY)ERK1/2 by either PTPs or protein Ser-/Thr-phosphatases, but were assumed to be enzymically-inactive. (pT-E-Y)ERK1/2 were predominantly cytoplasmic and (T-E-pY)ERK1/2 were predominantly nuclear. Additionally, (T-EpY)ERK1/2 formed by the action of PP2A phosphatase have been detected in the nuclei of cell lines but also co-localised with the Golgi apparatus during the G 2 /M phase of the cell cycle, when they may be involved in Golgi disassembly [33, 34] . Their role in the Golgi seemed to be dependent on the monophosphorylation itself rather than ERK1/2 activity.
Other studies using a Tyr-to Phe mutation in the T-G-Y phosphorylation motif of p38-MAPKα indicated that it can be enzymically-activated [to (pT-G-F)p38-MAPKα, etc.]
by its MAPK kinase in vitro, but its activity is only ~5% that of (pT-G-pY)p38-MAPK [35] . Our data do not conflict with the accepted ordered phosphorylation mechanism. The appearance of (pT-E-Y)ERK1/2 is delayed relative to (pT-E-pY)ERK1/2 (Fig. 3) , consistent with obligate initial phosphorylation of the Tyr-residue. As suggested [10] , it seems likely that (pT-E-Y)ERK1/2 are generated through dephosphorylation of (pT-E-pY)ERK1/2 by one or more PTPs. On the assumption that a 'classical' Cys-dependent PTP dephosphorylates 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   22 (pT-E-pY)ERK1/2, ~15 candidates have been identified as being expressed in cardiac myocytes by our transcriptomics data (A. Clerk, unpublished data). A final question relates to the potential role of (pT-E-Y)ERK1/2 in vivo. The biological role(s) of (pT-E-Y)ERK1/2 is unclear. Given that pY-185 in ERK2 forms part of the substrate recognition pocket, (pT-E-Y)ERK1/2 may differ from (pT-E-pY)ERK1/2 in terms of substrate specificity . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   23 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Fig. 1 . Immunofluorescence microscopy of (pT-E-pY) ERK1/2 in cardiac myocytes exposed to endothelin-1 (ET-1). Following exposure to ET-1 (100 nM) for the times indicated, myocytes were stained for nuclei (blue), (pT-E-pY)ERK1/2 (green, Sigma-Aldrich antibody), or actin filaments (red). The combined overlay images are also shown. Representative fields 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 25 (out of 3) from an individual experiment are shown and the experiment was repeated 3 times on separate preparations of myocytes. Scale bar = 50 µm.
FIGURE LEGENDS
Fig. 2.
MonoQ FPLC of ERK1/2 in extracts of cardiac myocytes. Myocytes were exposed to 100 nM ET-1 for 5 min, 1 µM PMA for 5 min, or to 2 µM PD184352 for 15 min followed by 100 nM ET-1 for 5 min, and extracts were applied to MonoQ columns. Following a 5 ml isocratic wash, the NaCl concentration was increased in a stepwise fashion to 0.1 M (2 ml).
ERK1/2 activities were eluted with a linear NaCl gradient (0.1 M-0.22 M NaCl, 12 ml).
Flow rate was 0.5 ml/min, 0.25 ml fractions were collected and MBP kinase activities 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 . MBP kinase activities in fractions were measured and peaks of activity were integrated. In all cases, ET-1 standards (myocytes exposed to 100 nM ET-1 for 5 min) were included, and the total activity or the activity in each peak was expressed as a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 relative to the ET-1 total activity standard] were plotted against total activity relative to the ET-1 standard (Fig. 6A) for each agonist. All results are means ± S.E.M. F, points were fitted to a fourth-order polynomial non-linear regression equation (r 2 = 0.98). G, points were fitted to a linear regression. In both cases, the lines were forced through the origin.
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